Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of scleroderma~* Agrees to use an effective form of contraception for 1 month prior to study entry, throughout the study, and for 60 days after completing the study~* Positive serum anti-nuclear antibody titer~Exclusion Criteria:~* Systemic sclerosis-like illnesses associated with environmental, ingested, or injected agents or with other connective tissue diseases~* Significant existing damage to any of the following internal organs:~  * Kidneys, defined as a serum creatinine level greater than 2 mg/dl or renal crisis~ * Lungs, defined as needing supplemental oxygen~ * Heart, defined as left ventricular ejection fraction less than or equal to 40%~ * Gut, defined as pseudo-obstruction or malabsorption requiring total parental nutrition~* Concurrent interventional therapy that might independently influence the outcome of this trial (e.g., D-penicillamine, cyclosporine, interferon-γ, methotrexate, or photophorosis)~* Clinically significant and inadequately medically treated concurrent endocrine, blood, liver, lung, or kidney diseases~* Pregnant~* Recent drug or alcohol abuse~* Documented noncompliance~* Significant psychiatric history~* Therapy with another investigational drug within 4 weeks prior to study entry~* Screening laboratory results exceeding the following limits: hemoglobin level less than 7 gm/dl; white blood cell level less than 3,000/nl; platelet count less than 50/nl; alanine aminotransferase (ALT) level greater than 65 U/L; creatinine level greater than 2 mg/dl

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive thalidomide.
- 2 (Type: PLACEBO_COMPARATOR): Participants will receive placebo thalidomide.

Based on this trial design, predict the completion outcome and termination type (if applicable).